3 most recent filings and news items mentioning RLMD. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/RLMD/news?limit=20"
Pull RLMD filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayRelmada Therapeutics reported second-quarter 2026 financial results and business updates, including advancing NDV-01 toward an IND target and reporting a $217.7 million cash balance.
View filing at SEC.gov →Relmada Therapeutics announced the appointment of Bipin Dalmia, PhD, as Chief Business Officer to lead strategy and business development for its NDV-01 therapy. This leadership change supports the company's growth and commercialization focus.
View filing at SEC.gov →Relmada Therapeutics, Inc. filed an amended and restated certificate of incorporation with Nevada Secretary of State on May 28, 2026, with stockholder approval of 62.04% voting in favor. The amendment modifies the company's authorized shares and corporate structure.
View filing at SEC.gov →